Abstract:ID 87867 Poster Board 474 The combined inhibition of soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH) represents a novel approach to non-opioid pain management, drawing from the known functions of these enzymes in pain and inflammatory pathways. Using multi-target directed ligands (MTDLs), a medicinal chemistry approach where a single drug modulates two or more biological targets simultaneously, our lab previously identified several benzothiazole-phenyl MTDLs with potent dual sEH and FAAH inhibition. Here, we report several in vivo evaluations of our previously identified dual sEH/FAAH inhibitor SP 4-5, the data received from National Institute of Mental Health's Psychoactive Drug Screening Program (PDSP) and a follow-up structure-activity relationship (SAR) study of quinolinyl-phenyl-based MTDLs that were synthesized using a microwave-assisted Suzuki coupling reaction. SP 4-5 was evaluated against persistent inflammatory pain. An intraplantar injection of Complete Freund's Adjuvant (CFA) was used to induce hindpaw inflammation. 1 and 3 mg/kg SP4-5 were administered 24 hours after inflammation. Neither dose alleviated mechanical or thermal hypersensitivity. However, when administered 2.5 hours after CFA, 3 mg/kg SP4-5 increased mechanical withdrawal thresholds indicating antinociception. In addition, PDSP screening showed that SP 4-5 does not bind to delta, mu and kappa opioid receptors. Our SAR study showed that quinoline moiety can successfully replace benzothiazole ring yielding potent compounds in human FAAH and human, rat, and mouse sEH inhibition assays. The most potent dual sEH/FAAH inhibitor identified in this study, JA112, showed inhibition potency in the low nanomolar range (1.7 nM -17.2 nM) for human FAAH, human sEH, rat sEH and mouse sEH enzymes. JA-112 was evaluated for its ability to reverse acute inflammatory induced by an intraplantar injection of dilute formalin. This revealed that JA-112 produces antinociception against formalin-induced inflammatory pain. Further, the differences observed between Phase 1 and Phase 2 of the Formalin Test indicate that JA-112 produces antinociception in a manner consistent with drugs that prevent pro-inflammatory states such as non-steroidal anti-inflammatory drugs (i.e., in non-opioid manner). Future experiments will investigate the effects of JA-112 against persistent inflammatory pain states and determine any adverse effects. Research reported in this publication was supported by the National Institute of General Medical Sciences of the National Institutes of Health under award number 1 R16GM149204-01.

Design of a Stable Cyclic Peptide Analgesic Derived from Sunflower Seeds that Targets the κ-Opioid Receptor for the Treatment of Chronic Abdominal Pain

Structural Basis for Bifunctional Peptide Recognition at Human Δ-Opioid Receptor

A Synthetic Peptide Exerts Nontolerance-Forming Antihyperalgesic and Antidepressant Effects in Mice

Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives As Μ/κ Opioid Receptor Dual Selective Ligands.

PD-1: A New Candidate Target for Analgesic Peptide Design

Development of a Selective Peptide κ-Opioid Receptor Antagonist by Late-Stage Functionalization with Cysteine Staples

Identification and characterization of plant-derived alkaloids, corydine and corydaline, as novel mu opioid receptor agonists

Building a better analgesic: multifunctional compounds that address injury-induced pathology to enhance analgesic efficacy while eliminating unwanted side effects

Design, Synthesis, and Biological Evaluation of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan Derivatives As Peripheral Selective Μ Opioid Receptor Agents.

Analgesic Peptides: From Natural Diversity to Rational Design

Pharmacological Characterization of 17-Cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-[(3'-fluoro-4'-pyridyl)acetamido]morphinan (NFP) As a Dual Selective MOR/KOR Ligand with Potential Applications in Treating Opioid Use Disorder.

Multitargeted Opioid Ligand Discovery as a Strategy to Retain Analgesia and Reduce Opioid-Related Adverse Effects

Identification and Pharmacological Characterization of a Low-Liability Antinociceptive Bifunctional MOR/DOR Cyclic Peptide

In Vitro and In Vivo Pharmacological Profiles of LENART01, a Dermorphin–Ranatensin Hybrid Peptide

An Analgesic Peptide H-20 Attenuates Chronic Pain Via the PD-1 Pathway with Few Adverse Effects.

Antinociceptive Efficacy of the µ-Opioid/Nociceptin Peptide-Based Hybrid KGNOP1 in Inflammatory Pain without Rewarding Effects in Mice: An Experimental Assessment and Molecular Docking

Peptide-derived ligands for the discovery of safer opioid analgesics

Computer‐Aided Design of Opioid Receptors Dual Action Ligands with Mitigated Side Effects As a Potential New Avenue for Analgesic and Substance Abuse Treatment

Discovery, Structure–Activity Relationship, and Mechanistic Studies of 1-((3 R ,4 S )-3-((Dimethylamino)methyl)-4-hydroxy-4-(3-methoxyphenyl)piperidin-1-yl)-2-(2,4,5-trifluorophenyl)ethan-1-one as a Novel Potent Analgesic

Controlling opioid receptor functional selectivity by targeting distinct subpockets of the orthosteric site

Multitarget-Directed Ligands with Soluble Epoxide Hydrolase and Fatty Acid Amide Hydrolase Inhibitory Activities for Treatment of Chronic Pain